---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-052729"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-05-27T23:59:59+00:00"
generated_at: "2026-05-20T10:12:13.245103+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma gets FDA guidance on bird flu drug tivoxavir; details stockpiling plans; cash $15.9M

## Summary
- Received FDA guidance on path forward for tivoxavir marboxil (TXM) for bird flu and seasonal flu; pursuing Animal Rule for accelerated approval.
- Preclinical data: single oral dose of TXM protected against lethal H5N1 (dairy-worker strain) in mice, ferrets, and non-human primates.
- Phase 1 data: single 480 mg dose maintained plasma levels above EC90 for ~3 weeks; no treatment-related adverse events.
- US strategic stockpile estimated at 300-600 million doses; company discussing TXM inclusion with BARDA.
- Cash and equivalents of $15.9M as of March 31, 2025; expected runway into Q1 2026.

## SEC filing metadata
- accession: 0001104659-25-052729
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-05-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925052729/0001104659-25-052729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925052729/tm2516160d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-052729
- JSON: https://secwatch.observer/filing/0001104659-25-052729.json
- Plain text: https://secwatch.observer/filing/0001104659-25-052729.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.